Mayukh Sukhatme - 23 Dec 2024 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role: Pres&Chief Investment Officer, Director
Signature: By: /s/ Jo Chen, as Attorney-in-Fact for Mayukh Sukhatme
Issuer symbol: ROIV
Transactions as of: 23 Dec 2024
Net transactions value: -$7,229,726
Form type: 4
Filing time: 26 Dec 2024, 21:00:42 UTC
Previous filing: 20 Dec 2024
Next filing: 19 Dec 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ROIV	Common Shares	Options Exercise	$41,565	+10,796	+0.06%	$3.85	18,847,343	23 Dec 2024	Direct
transaction	ROIV	Common Shares	Sale	$129,552	-10,796	-0.06%	$12.00	18,836,547	23 Dec 2024	Direct	F1
transaction	ROIV	Common Shares	Options Exercise	$715,892	+185,946	+0.99%	$3.85	19,022,493	24 Dec 2024	Direct
transaction	ROIV	Common Shares	Sale	$2,231,352	-185,946	-0.98%	$12.00	18,836,547	24 Dec 2024	Direct	F1
transaction	ROIV	Common Shares	Options Exercise	$2,654,556	+689,495	+3.7%	$3.85	19,526,042	26 Dec 2024	Direct
transaction	ROIV	Common Shares	Sale	$8,280,835	-689,495	-3.5%	$12.01	18,836,547	26 Dec 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ROIV	Stock Option (Right to Buy)	Options Exercise	$0	-10,796	-0.07%	$0.000000	16,099,804	23 Dec 2024	Common Stock	10,796	$3.85	Direct	F2
transaction	ROIV	Stock Option (Right to Buy)	Options Exercise	$0	-185,946	-1.2%	$0.000000	15,913,858	24 Dec 2024	Common Stock	185,946	$3.85	Direct	F2
transaction	ROIV	Stock Option (Right to Buy)	Options Exercise	$0	-689,495	-4.3%	$0.000000	15,224,363	26 Dec 2024	Common Stock	689,495	$3.85	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
F2	Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

Content

The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).